Genprex Management
Management criteria checks 2/4
Genprex's CEO is John Varner, appointed in Aug 2012, has a tenure of 11.67 years. total yearly compensation is $2.53M, comprised of 22% salary and 78% bonuses, including company stock and options. directly owns 1% of the company’s shares, worth $40.41K. The average tenure of the management team and the board of directors is 3.1 years and 4.1 years respectively.
Key information
John Varner
Chief executive officer
US$2.5m
Total compensation
| CEO salary percentage | 22.0% |
| CEO tenure | 11.7yrs |
| CEO ownership | 1.0% |
| Management average tenure | 3.1yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?
Aug 16
Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation
Jan 31Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans
Oct 12Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer
Aug 15We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate
Jun 14Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation
Feb 09Genprex: Limited Clinical Data To Justify Risk
Nov 19We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth
Oct 27Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans
Jun 11Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%
May 05Genprex' stock jumps after corporate update
Feb 01Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials
Jan 13Genprex completes manufacturing scale-up of lung cancer therapy
Dec 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$31m |
| Sep 30 2023 | n/a | n/a | -US$31m |
| Jun 30 2023 | n/a | n/a | -US$30m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$3m | US$557k | -US$24m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$21m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$2m | US$480k | -US$21m |
| Sep 30 2021 | n/a | n/a | -US$19m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$19m |
| Dec 31 2020 | US$2m | US$488k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$15m |
| Jun 30 2020 | n/a | n/a | -US$15m |
| Mar 31 2020 | n/a | n/a | -US$14m |
| Dec 31 2019 | US$659k | US$400k | -US$11m |
| Sep 30 2019 | n/a | n/a | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$11m |
| Mar 31 2019 | n/a | n/a | -US$14m |
| Dec 31 2018 | US$1m | US$338k | -US$12m |
| Sep 30 2018 | n/a | n/a | -US$10m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$3m |
| Dec 31 2017 | US$334k | US$300k | -US$3m |
Compensation vs Market: John's total compensation ($USD2.53M) is above average for companies of similar size in the US market ($USD668.06K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Varner (66 yo)
11.7yrs
Tenure
US$2,532,399
Compensation
Mr. John Rodney Varner is a co-founder of Genprex, Inc. He has been the Chief Executive Officer and Chairman of Genprex, Inc. since August 2012 and has been its President since August 10, 2020. He served a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.7yrs | US$2.53m | 1.0% $ 40.4k | |
| Chief Financial Officer | 7.6yrs | US$1.14m | 0.35% $ 14.2k | |
| Senior Vice President of Human Resources | 2.3yrs | no data | no data | |
| Senior Vice President of Intellectual Property & Licensing | 3.6yrs | no data | no data | |
| Chief Medical Officer | 2.6yrs | no data | 0.25% $ 10.2k | |
| Senior Vice President of Regulatory Affairs & Quality | less than a year | no data | no data | |
| Chairman of Scientific & Medical Advisory Board | no data | no data | no data |
3.1yrs
Average Tenure
66yo
Average Age
Experienced Management: GNPX's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.7yrs | US$2.53m | 1.0% $ 40.4k | |
| Chairman of Scientific & Medical Advisory Board | no data | no data | no data | |
| Independent Director | 4.1yrs | US$150.00k | 0.046% $ 1.9k | |
| Strategic Advisor to the Board of Directors | 11.8yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | 3.2yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Independent Director | 4.1yrs | US$140.00k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$150.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.4yrs | no data | no data | |
| Member of Clinical Advisory Board | 3.2yrs | no data | no data |
4.1yrs
Average Tenure
66.5yo
Average Age
Experienced Board: GNPX's board of directors are considered experienced (4.1 years average tenure).